Morgan Stanley Maintains Overweight on BioNTech, Lowers Price Target to $106
Benzinga Newsdesk 11 hours ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Terence Flynn maintains BioNTech (NASDAQ:BNTX) with a Overweight and lowers the price target from $114 to $106.
Morgan Stanley analyst Terence Flynn maintains BioNTech (NASDAQ:BNTX) with a Overweight and lowers the price target from $114 to $106.